Myelodysplastic Syndrome: Low Blood Counts, Bone Marrow Testing, and Treatment Options

Myelodysplastic syndrome is a group of bone marrow disorders in which the body does not make enough healthy blood cells. It often causes low blood counts, and diagnosis usually includes blood tests and a bone marrow examination to guide treatment.

Overview

Myelodysplastic syndrome, often called MDS, is a group of disorders that affect the bone marrow. Bone marrow is the soft tissue inside bones where blood cells are made. In MDS, the marrow does not produce enough healthy, mature blood cells, so red blood cells, white blood cells, platelets, or all three may become low.

These low blood counts can lead to symptoms such as tiredness, frequent infections, or easy bleeding. In some people, MDS is found during routine blood tests before symptoms appear. The condition can vary widely: some cases remain stable for a long time, while others are more aggressive and need earlier treatment.

MDS is most often diagnosed in older adults, but it can occur at different ages. It is considered a bone marrow failure disorder and, in some patients, may progress to <a href="https://acibademinternational.com/diseases/acute-myeloid-leukemia/”>acute myeloid leukemia. Because the course of the condition differs from person to person, careful evaluation and follow-up are important.

Symptoms of myelodysplastic syndrome

Symptoms usually relate to which blood cell type is low. Low red blood cells can cause anemia, which often leads to fatigue, weakness, shortness of breath, dizziness, or pale skin. Low white blood cells may make infections more frequent or harder to clear. Low platelets can cause easy bruising, nosebleeds, bleeding gums, or pinpoint red spots on the skin.

Some people notice a gradual decline in energy rather than a sudden illness. Others may only learn they have MDS after a blood test shows persistent abnormalities. Because these symptoms can also happen in many other conditions, they do not confirm MDS on their own.

• Fatigue or reduced exercise tolerance
• Shortness of breath
• Frequent or unusual infections
• Easy bruising or prolonged bleeding
• Pale skin or dizziness
• Unexplained low blood counts on routine testing

If symptoms become more noticeable over time, a medical evaluation is helpful. Early assessment can clarify whether the problem is related to nutritional deficiencies, medications, infection, another blood disorder, or MDS.

Causes and risk factors

In many people, there is no single clear cause of myelodysplastic syndrome. The disorder develops when changes occur in bone marrow stem cells, affecting how blood cells grow and mature. These changes may involve chromosomes or gene mutations identified during specialized testing.

Age is one of the most important risk factors, and MDS is more common in older adults. Some cases happen after prior chemotherapy or radiation therapy for another cancer; this is sometimes called therapy-related MDS. Long-term exposure to certain chemicals, such as benzene, may also increase risk.

Other bone marrow and blood conditions can sometimes be considered during evaluation, including aplastic anemia or leukemia-related disorders. Doctors also assess for vitamin deficiencies, chronic inflammation, infections, liver or kidney disease, and medication effects, since these can cause similar blood count changes.

Having a risk factor does not mean a person will develop MDS, and many people diagnosed with it have no obvious trigger. A hematologist uses the full clinical picture, blood tests, marrow findings, and genetic results to understand the condition more clearly.

How diagnosis is confirmed

Diagnosis usually begins with a complete blood count and a review of the blood smear under a microscope. These tests help show whether red blood cells, white blood cells, or platelets are low and whether the cells look abnormal. Additional blood work may check iron, vitamin B12, folate, kidney and liver function, and other possible causes of low counts.

A bone marrow aspiration and biopsy are typically needed to confirm MDS. During this test, a small sample of liquid marrow and a core of marrow tissue are taken, usually from the hip bone. The sample is examined for cell appearance, the number of immature cells called blasts, and how well different blood-forming cells are developing.

Genetic and molecular tests are also important. Cytogenetic testing can identify chromosome changes, and newer molecular tests may detect gene mutations that affect prognosis and treatment planning. These results help classify the subtype of MDS and estimate how likely the disease is to remain stable or progress.

Doctors often use risk scoring systems to guide decisions about treatment intensity and follow-up. This means that diagnosis is not only about naming the condition but also about understanding how it is likely to behave over time.

Treatment options

Treatment for myelodysplastic syndrome is individualized. Some people with mild disease and few symptoms may only need careful monitoring with regular blood tests. This is sometimes called watchful waiting or active surveillance. The goal is to avoid unnecessary treatment while still responding promptly if blood counts worsen or symptoms develop.

Supportive care is a major part of management. It may include blood transfusions for anemia, platelet transfusions when bleeding risk is high, and antibiotics for infections. Some patients benefit from medicines that stimulate blood cell production, such as growth factors, especially when anemia is a main issue.

For higher-risk disease, doctors may recommend drug treatments that aim to improve marrow function, reduce transfusion needs, or slow progression. Depending on the person’s situation, care may involve chemotherapy, targeted approaches, or other disease-modifying medicines used by hematology specialists. If there is concern about progression to leukemia, closer monitoring and more intensive treatment planning may be needed.

An allogeneic bone marrow transplantation or stem cell transplant is the only treatment with curative potential for selected patients, but it is not suitable for everyone. Eligibility depends on age, general health, donor availability, subtype of MDS, and overall risk. In some cases, hospital teams may also use blood transfusion support as an ongoing part of care. Treatment decisions are best made with a hematologist who can explain expected benefits and risks.

Living with MDS: self-care and ongoing monitoring

Living with myelodysplastic syndrome often involves regular follow-up. Blood counts may need to be checked at intervals based on the severity of the condition and the type of treatment being used. Monitoring helps doctors detect changes early and adjust care before complications become more serious.

Self-care can support overall well-being, although it does not replace medical treatment. Good nutrition, adequate rest, gentle physical activity as tolerated, and attention to infection prevention are helpful. People with low white blood cells may be advised to report fever promptly and to follow practical hygiene measures, especially during periods of increased infection risk.

Those with anemia may need to pace activities and plan rest periods. People with low platelets should take extra care to avoid injury and ask their doctor before using medicines that increase bleeding risk. Vaccination plans, dental care, travel considerations, and medication reviews should all be discussed with the treating team.

Emotional support also matters. A new diagnosis of a chronic blood disorder can feel overwhelming, especially when monitoring continues for months or years. Clear communication with the care team, involvement of family members, and access to counseling or support groups can make long-term management easier.

When to see a doctor

A person should seek medical advice if they have persistent fatigue, unexplained bruising, repeated infections, or bleeding that seems unusual. These symptoms do not always mean myelodysplastic syndrome, but they do deserve evaluation, especially if they continue or worsen.

Urgent medical attention is important for fever, shortness of breath at rest, chest pain, heavy bleeding, black or bloody stools, confusion, or severe weakness. People already diagnosed with MDS should ask their care team which symptoms require same-day contact or emergency care.

Because MDS can range from slow-growing to more serious disease, specialist assessment is valuable. Near the end of the care journey, some patients may benefit from multidisciplinary evaluation; Acibadem International’s hematology specialists in JCI-accredited hospitals diagnose and treat myelodysplastic syndrome for international patients.

Early evaluation, accurate bone marrow testing, and a personalized treatment plan can help people understand their options and manage the condition with greater confidence.

Frequently asked questions

Is myelodysplastic syndrome a cancer?

Myelodysplastic syndrome is generally considered a type of blood and bone marrow cancer or a closely related marrow disorder, depending on the classification used. It affects how blood cells are formed and, in some cases, can progress to acute myeloid leukemia.

What is the main test for myelodysplastic syndrome?

Blood tests are often the first clue, but a bone marrow aspiration and biopsy are usually needed to confirm the diagnosis. These tests help doctors examine cell development, count blasts, and perform genetic studies that guide treatment.

Can myelodysplastic syndrome cause anemia?

Yes. Anemia is one of the most common problems in myelodysplastic syndrome because the marrow may not make enough healthy red blood cells. This can lead to tiredness, weakness, dizziness, or shortness of breath.

Is myelodysplastic syndrome curable?

For selected patients, an allogeneic stem cell or bone marrow transplant offers the possibility of cure. However, many people are treated with supportive care or medicines to control symptoms, improve blood counts, and slow disease progression.

Does everyone with MDS need treatment right away?

No. Some people with lower-risk MDS and few symptoms may be monitored closely without immediate treatment. The decision depends on blood counts, symptoms, marrow findings, genetic results, and overall health.

What happens if myelodysplastic syndrome is left untreated?

If treatment is needed but delayed, low blood counts may lead to worsening fatigue, infections, or bleeding problems. In some cases, the disease may become more aggressive or progress, which is why regular follow-up with a hematologist is important.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.